vs
Side-by-side financial comparison of SOLESENCE, INC. (SLSN) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $12.5M, roughly 1.6× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -84.4%, a 85.7% gap on every dollar of revenue. On growth, SOLESENCE, INC. posted the faster year-over-year revenue change (-0.7% vs -65.2%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs 6.4%).
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
SLSN vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $20.6M |
| Net Profit | $163.0K | $-17.3M |
| Gross Margin | 27.5% | — |
| Operating Margin | 1.5% | -106.0% |
| Net Margin | 1.3% | -84.4% |
| Revenue YoY | -0.7% | -65.2% |
| Net Profit YoY | 129.2% | -173.8% |
| EPS (diluted) | $0.00 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.5M | — | ||
| Q3 25 | $14.6M | — | ||
| Q2 25 | $20.4M | — | ||
| Q1 25 | $14.6M | $20.6M | ||
| Q4 24 | $12.6M | $37.4M | ||
| Q3 24 | $16.9M | $19.6M | ||
| Q2 24 | $13.0M | $94.7M | ||
| Q1 24 | $9.9M | $59.1M |
| Q4 25 | $163.0K | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $80.0K | $-17.3M | ||
| Q4 24 | $-559.0K | $1.1M | ||
| Q3 24 | $3.0M | $-14.0M | ||
| Q2 24 | $856.0K | $55.0M | ||
| Q1 24 | $893.0K | $23.5M |
| Q4 25 | 27.5% | — | ||
| Q3 25 | 23.1% | — | ||
| Q2 25 | 28.9% | — | ||
| Q1 25 | 23.1% | — | ||
| Q4 24 | 22.0% | — | ||
| Q3 24 | 36.2% | — | ||
| Q2 24 | 28.7% | — | ||
| Q1 24 | 36.3% | — |
| Q4 25 | 1.5% | — | ||
| Q3 25 | -5.4% | — | ||
| Q2 25 | 9.4% | — | ||
| Q1 25 | 1.8% | -106.0% | ||
| Q4 24 | -1.8% | -15.7% | ||
| Q3 24 | 19.0% | -110.7% | ||
| Q2 24 | 8.0% | 56.4% | ||
| Q1 24 | 11.3% | 35.7% |
| Q4 25 | 1.3% | — | ||
| Q3 25 | -7.7% | — | ||
| Q2 25 | 13.1% | — | ||
| Q1 25 | 0.5% | -84.4% | ||
| Q4 24 | -4.4% | 3.0% | ||
| Q3 24 | 18.1% | -71.7% | ||
| Q2 24 | 6.6% | 58.1% | ||
| Q1 24 | 9.0% | 39.7% |
| Q4 25 | $0.00 | — | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $0.04 | — | ||
| Q1 25 | $0.00 | $-0.42 | ||
| Q4 24 | $0.00 | $-0.20 | ||
| Q3 24 | $0.04 | $-0.35 | ||
| Q2 24 | $0.01 | $1.55 | ||
| Q1 24 | $0.02 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.6M | $417.3M |
| Total Assets | $50.1M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3M | — | ||
| Q3 25 | $429.0K | — | ||
| Q2 25 | $4.1M | — | ||
| Q1 25 | $1.8M | $67.8M | ||
| Q4 24 | $1.4M | $101.2M | ||
| Q3 24 | $2.9M | $78.0M | ||
| Q2 24 | $2.4M | $185.3M | ||
| Q1 24 | $2.0M | $68.4M |
| Q4 25 | $17.6M | — | ||
| Q3 25 | $17.2M | — | ||
| Q2 25 | $18.2M | — | ||
| Q1 25 | $15.2M | $417.3M | ||
| Q4 24 | $14.9M | $428.7M | ||
| Q3 24 | $15.2M | $422.4M | ||
| Q2 24 | $11.9M | $429.9M | ||
| Q1 24 | $5.0M | $269.4M |
| Q4 25 | $50.1M | — | ||
| Q3 25 | $54.0M | — | ||
| Q2 25 | $60.0M | — | ||
| Q1 25 | $57.0M | $486.5M | ||
| Q4 24 | $50.0M | $526.3M | ||
| Q3 24 | $48.0M | $554.6M | ||
| Q2 24 | $40.8M | $582.0M | ||
| Q1 24 | $38.5M | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | 11.16× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | — | ||
| Q3 25 | $-2.5M | — | ||
| Q2 25 | $-654.0K | — | ||
| Q1 25 | $-7.2M | $-38.5M | ||
| Q4 24 | $2.2M | $-31.6M | ||
| Q3 24 | $4.2M | $-24.3M | ||
| Q2 24 | $-565.0K | $39.8M | ||
| Q1 24 | $-3.9M | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | $-404.0K | $-32.2M | ||
| Q3 24 | $2.8M | $-24.9M | ||
| Q2 24 | $-1.0M | $38.8M | ||
| Q1 24 | $-3.9M | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | -3.2% | -86.2% | ||
| Q3 24 | 16.6% | -127.3% | ||
| Q2 24 | -8.0% | 41.0% | ||
| Q1 24 | -39.9% | -44.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | 20.6% | 1.7% | ||
| Q3 24 | 8.3% | 3.3% | ||
| Q2 24 | 3.7% | 1.1% | ||
| Q1 24 | 0.9% | 1.4% |
| Q4 25 | 11.16× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.25× | — | ||
| Q1 25 | -90.26× | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | -0.66× | 0.72× | ||
| Q1 24 | -4.32× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
